Summary
The purpose of this paper is to challenge the uncritical use of incremental cost-outcomes ratios as decision variables. A scenario is presented which describes conditions under which increasing costs per unit of outcome prevail. Marginal costs increase as the proportion of patients treated under a given therapy increases. If the health system’s objective is to maximise health benefits then patients will be switched until the marginal benefits per dollar expended are equal between the 2 therapies. In an example where the costs of the new therapy are greater, for a given proportion of patients treated, patients are switched from the existing to the new therapy until an equilibrium is achieved in the allocation of therapies among the treating population. At this point, the overall costs of treatment are at a minimum. This outcome could only be predicted if the underlying cost-outcomes functions are known and the consequent patterns of therapy substitution and cost impacts assessed. The paper concludes by raising concerns as to the role of incremental cost-outcomes ratios as decision variables where increasing costs may be expected to prevail and there is failure to consider the implications of these increasing costs in formulary decision making. If increasing costs are present then conventional cost-outcomes and incremental cost-outcomes ratios are of limited utility as decision variables in the choice of therapy options.
Similar content being viewed by others
References
Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. PharmacoEconomics 1996; 9(2): 113–20
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987
Bootman JL, Townsend RJ, McGhan WE. Principles of pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Langley, P.C. Cost Effectiveness and the Allocation of Therapies in a Treating Population. Pharmacoeconomics 10, 93–98 (1996). https://doi.org/10.2165/00019053-199610010-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199610010-00009